SARS-CoV-2 Antiviral Prescribing Gaps Among Nonhospitalized High-Risk Adults.

Matthew E LevyEvanette BurrowsVanessa ChilundaPamala A PawloskiPhillip R HeatonJoseph GrzymskiJason D GoldmanLisa M McEwenDana WymanAndrew Dei RossiHang DaiMagnus IsakssonNicole L WashingtonTracy BaslerKevin TsanJason NguyenJimmy RamirezEfren SandovalWilliam LeeJames LuShishi Luo

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)

Within a multistate clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022-June 2023 among nonhospitalized patients with SARS-CoV-2 with risk factors for severe COVID-19. Among 3247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/ritonavir, 11.9% molnupiravir, 0.5% remdesivir), highlighting the need to identify and address treatment barriers.

Keyphrases

sars cov
respiratory syndrome coronavirus
primary care
coronavirus disease
adverse drug
antiretroviral therapy
drug induced
electronic health record